Living up to the hype around GLP-1 obesity treatments is tough enough. But Eli Lilly needs to hit its own targets.
Related Posts
‘Our country is in danger’: French PM takes confidence vote gamble over budget woes
France’s CAC 40 index plunged 2% on Tuesday as analysts assessed the potential for a fresh period of political instability.
European markets set to start the week on a negative note as tariff threat weighs
Join CNBC for live updates on European markets.
Josh Brown says Microsoft’s breakout is unique, don’t expect that to apply to every other Big Tech
The co-founder and CEO of Ritholtz Wealth Management said it’s too soon for investors to extrapolate what could be an idiosyncratic story at Microsoft to […]